Suchergebnisse - "Goel, Utkarsh"

PubPharm (21)

1

Efficacy and safety of daratumumab, pomalidomide, and dexamethasone versus daratumumab, carfilzomib, and dexamethasone in daratumumab-naïve relapsed multiple myeloma

enthalten in: European journal of haematology | 2024

von Dima, D. | Mansour, R. | Davis, J. | +9

2

Outcomes of patients with multiple myeloma refractory to standard dose vs low dose lenalidomide

enthalten in: Blood cancer journal | 2024

von Goel, U. | Charalampous, C. | Kapoor, P. | +18

3

Efficacy and safety of daratumumab, pomalidomide, and dexamethasone versus daratumumab, carfilzomib, and dexamethasone in daratumumab‐naïve relapsed multiple myeloma

enthalten in: European Journal of Haematology | 2024

von Dima, D. | Mansour, R. | Davis, J. | +9

4

Comparison of daratumumab-based regimens as second-line therapy in relapsed/refractory multiple myeloma

enthalten in: Blood cancer journal | 2023

von Charalampous, C. | Goel, U. | Kapoor, P. | +19

5

Outcomes of patients with primary refractory multiple myeloma in the era of triplet and quadruplet induction therapy

enthalten in: Blood advances | 2023

von Charalampous, C. | Goel, U. | Kapoor, P. | +19

6

Thrombosis in multiple myeloma : Risk estimation by induction regimen and association with overall survival

enthalten in: American journal of hematology | 2023

von Charalampous, C. | Goel, U. | Kapoor, P. | +18

7

Defining drug/drug class refractoriness vs lines of therapy in relapsed/refractory multiple myeloma

enthalten in: Blood cancer journal | 2023

von Goel, U. | Charalampous, C. | Kapoor, P. | +18

8

Impact of the time interval between end of induction and autologous hematopoietic transplantation in newly diagnosed patients with multiple myeloma

enthalten in: Bone marrow transplantation | 2023

von Charalampous, C. | Goel, U. | Gertz, M. | +10

9

An update on the safety of ixazomib for the treatment of multiple myeloma

enthalten in: Expert opinion on drug safety | 2022

von Goel, U. | Kumar, S.

10

Utility of PET/CT in assessing early treatment response in patients with newly diagnosed multiple myeloma

enthalten in: Blood advances | 2022

von Charalampous, C. | Goel, U. | Broski, S. | +19